Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline’s efficacy in reducing symptoms related t...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdener, Ayşe Elif, Rivkin, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628681/
https://www.ncbi.nlm.nih.gov/pubmed/29033544
http://dx.doi.org/10.2147/DDDT.S127405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628681/
https://www.ncbi.nlm.nih.gov/pubmed/29033544
http://dx.doi.org/10.2147/DDDT.S127405

Ejemplares similares